Objective Analysis of Poly-L-Lactic Acid Injection Efficacy in Different Settings

被引:6
作者
Byun, Sang-Young [1 ,2 ]
Seo, Koo-Il [3 ]
Shin, Jung-Won [1 ,2 ]
Kwon, Soon-Hyo [1 ,2 ]
Park, Mi-Sook [1 ,2 ]
Lee, Joshua [4 ]
Park, Kyoung-Chan [1 ,2 ]
Na, Jung-Im [1 ,2 ]
Huh, Chang-Hun [1 ,2 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Dermatol, Songnam, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Songnam, South Korea
[3] Modelo Clin, Seoul, South Korea
[4] Emory Univ, Coll Med, Atlanta, GA 30322 USA
关键词
HIV-INFECTED PATIENTS; FACIAL LIPOATROPHY; POLYLACTIC ACID; OPEN-LABEL; NASOLABIAL FOLD; SAFETY; FILLER; IMPLANT;
D O I
10.1097/DSS.0000000000000552
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUND Poly-L-lactic acid (PLLA) filler is known to have continuous volume effect. OBJECTIVE The objective of this study is to analyze objective volume effect of PLLA in different settings of injection schedule on the cheek. METHODS A split-face, evaluator-blind randomized study in 24 volunteers was conducted. One side was injected 3 times with 4 cc dose and the other side was injected 2 times with 6 cc dose per visit. Facial volume loss scale (FVLS) and Vectra were evaluated. RESULTS Measured average FVLS showed statistically significant improvement both in 3 and 2 times injection sides and maintained efficacy until 12 months. Vectra showed volume difference (cc) between before and after injection. In 3 times injection side, it was increased 2.12 (after 1 month) to 3.17 (after 12 months). In 2 times injection side, it was increased 2.26 (after 1 month) to 3.19 (after 12 months). Gradual volume improvement over 12 months was statistically significant in both sides. There was no statistically significant difference between 3 and 2 times injection in FVLS and Vectra. There was no severe adverse event. CONCLUSION Poly-L-lactic acid has continuous volume effect and there was no significant difference by injection times at the same total injection volume.
引用
收藏
页码:S314 / S320
页数:7
相关论文
共 24 条
[1]   Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients [J].
Borelli, C ;
Kunte, C ;
Weisenseel, P ;
Thoma-Greber, E ;
Korting, HC ;
Konz, B .
SKIN PHARMACOLOGY AND PHYSIOLOGY, 2005, 18 (06) :273-278
[2]   Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy [J].
Burgess, CM ;
Quiroga, RM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (02) :233-239
[3]   A randomized, multicenter, open-label study of poly-l-lactic acid for HIV-1 facial lipoatrophy [J].
Carey, Dianne L. ;
Baker, David ;
Rogers, Gary D. ;
Petoumenos, Kathy ;
Chuah, John ;
Easey, Nicole ;
Mahon, Kirsty ;
Cooper, David A. ;
Emery, Sean ;
Carr, Andrew .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (05) :581-589
[4]   An objective case definition of lipodystrophy in HIV-infected adults: a case-control study [J].
Carr, A ;
Emery, S ;
Law, I ;
Puls, R ;
Lundgren, JD ;
Powderly, WG ;
Carr, B ;
Cooper, DA ;
Grinspoon, S ;
Ioannidis, J ;
Lewis, R ;
Law, M ;
Lichtenstein, K ;
Murray, J ;
Pizzuti, D ;
Rozenbaum, W ;
Schambelan, M ;
Moore, A ;
Miller, J .
LANCET, 2003, 361 (9359) :726-735
[5]   Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients [J].
Duracinsky, Martin ;
Leclercq, Pascale ;
Herrmann, Susan ;
Christen, Marie-Odile ;
Dolivo, Marc ;
Goujard, Cecile ;
Chassany, Olivier .
BMC INFECTIOUS DISEASES, 2014, 14
[6]   The Use of Poly-L- Lactic Acid Filler in Facial Aesthetics [J].
Ezzat, Waleed H. ;
Keller, Gregory S. .
FACIAL PLASTIC SURGERY, 2011, 27 (06) :503-509
[7]   Three-Dimensional Volumetric Quantification of Fat Loss Following Cryolipolysis [J].
Garibyan, Lilit ;
Sipprell, William H., III ;
Jalian, H. Ray ;
Sakamoto, Fernanda H. ;
Avram, Mathew ;
Anderson, R. Rox .
LASERS IN SURGERY AND MEDICINE, 2014, 46 (02) :75-80
[8]   Cosmetic Use of Poly-l-lactic Acid: My Technique for Success and Minimizing Complications [J].
Goldman, Mitchel P. .
DERMATOLOGIC SURGERY, 2011, 37 (05) :688-693
[9]  
Guaraldi G, 2005, ANTIVIR THER, V10, P753
[10]   A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays [J].
Huang, Wei ;
Hennrick, Kenneth ;
Drew, Sally .
HUMAN PATHOLOGY, 2013, 44 (01) :29-38